Search
Buparlisib
go.drugbank.com/drugs/DB11666InvestigationalBuparlisib has been used in trials studying the treatment and basic science of Lymphoma, Metastases, Lung Cancer, Solid Tumors, and Breast Cancer, among others.
Categories: Heterocyclic Compounds, 1-Ring, Phosphatidylinositol 3-Kinases, antagonists & inhibitorsCurcumin
go.drugbank.com/drugs/DB11672ApprovedInvestigationalIt is a highly pleiotropic molecule that exhibits antibacterial, anti-inflammatory, hypoglycemic, antioxidant, wound-healing, and antimicrobial activities [A33166].
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesPyridoxamine
go.drugbank.com/drugs/DB11673InvestigationalPyridoxamine has been used in trials studying the treatment of Kidney Stones.
Categories: Vitamin B Complex, Heterocyclic Compounds, 1-RingFruquintinib
go.drugbank.com/drugs/DB11679ApprovedInvestigationalFruquintinib is a novel small-molecule anti-VEGFR that targets VEGFR-1,-2, and -3 to inhibit angiogenesis. … The first approach can be exemplified by [bevacizumab], a VEGF-A trap antibody.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-RingPacritinib
go.drugbank.com/drugs/DB11697ApprovedInvestigationalof both primary and secondary MF in patients with platelet counts < 50 x 10<sup>9</sup>/L. … [L40754] It provides a treatment option for patients who have MF with severe thrombocytopenia, which occurs in approximately one-third of MF patients and carries with it a particularly poor prognosis.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 InducersSetmelanotide
go.drugbank.com/drugs/DB11700ApprovedInvestigational[L24474] It is an agonist of the melanocortin 4 receptor. … [L24429] On May 4, 2023, it was approved by Health Canada.[L46327]
Categories: Melanocortin 4 Receptor Agonist, Melanocortin 4 Receptor AgonistsAcalabrutinib
go.drugbank.com/drugs/DB11703ApprovedInvestigationalTo date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. … [L10241] In August 2022, the FDA approved a new tablet formulation of Calquence, enabling the co-administration of this drug with proton pump inhibitors (PPIs).
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesProducts: CALQUENCE® 100MGEncorafenib
go.drugbank.com/drugs/DB11718ApprovedInvestigationalEncorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. … [L12216] This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: BRAFTOVI® 75 MG CÁPSULASEncenicline
go.drugbank.com/drugs/DB11726InvestigationalEncenicline has been investigated for the treatment of Cognition, Schizophrenia, Alzheimer's Disease, Cardiac Repolarization, and Central Nervous System Diseases.
Categories: Heterocyclic Compounds, 1-RingIcotinib
go.drugbank.com/drugs/DB11737Investigational. was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC). … Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers